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Abstract
Background: Viscosupplementation is a symptomatic treatment of the knee osteoarthritis based on the intra-
articular injection of hyaluronic acid (IAHA). Although many studies have investigated its effect on symptoms, few
clinical studies have focused on its effects on biologicals markers of cartilage metabolism. In this study, we assessed
the effect of an intra-articular injection of a reticulated hyaluronic acid compound on the level of a specific
biomarker of type II collagen degradation.
Methods: Eighty one patients with symptomatic knee osteoarthritis were included in this randomized placebo
controlled trial testing a reticulated hyaluronic acid (HA) with mannitol (KARTILAGE® CROSS, 16 mg/ml, one single
injection of 2.2 mL; IAHA) versus saline solution. Primary outcome was the percentage of patients with a reduction
of at least 10 nmol/l of serum Coll2-1 between baseline and day 90 (D90, 3 months after injection). Secondary
outcomes concerned clinical evaluation and tolerance to the study product.
Results: A significant effect of IAHA was revealed by the sensitivity analysis of the decrease in cartilage marker. In
the intention-to-treat population, the percentage of patients showing a decrease in the levels of serum Coll2-1
between inclusion and D90 showed was higher in HA (56.8%) than in placebo group (28.6%; P = 0.01). The same
significant difference was observed between groups in the per protocol population (57.1% vs 29.0%; P = 0.02)
corresponding to all patients having received the intra-articular injection (IA), being evaluated for the primary
outcome on D-10 and D90, and with no major defined deviation. No significant differences between groups were
observed on the changes in function (Lequesne index) or pain and on the number of adverse events.
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Conclusions: This is the first randomized double-blind placebo controlled trial showing that IA injection of
reticulated HA with mannitol in knee osteoarthritis patients can reduce the serum levels of Coll2-1, a marker specific
of type II collagen degradation. This finding suggests that IAHA may have a beneficial effect on cartilage
degradation and that Coll2-1 could be used for the assessment of a single intra-articular treatment in clinical trials.
Trial registration: NCT02951585; clinicaltrial.gov. Retrospectively registered on October 28, 2016.
Keywords: Viscosupplementation, Treatment, Type II collagen, Metabolism
Background
Osteoarthritis (OA) is one of the most common forms
of musculoskeletal disorders and one of the major cause
of pain and disability in the adult population [1]. It is a
progressive disorder characterized by synovium inflam-
mation, bone remodeling and degradation of the extra-
cellular matrix of articular cartilage [2, 3]. The knee is
the most affected joint by OA. It has a high prevalence
of 40% for men and 47% for women [4].
Intra-articular (IA) hyaluronic acid (HA) injections,
also known as viscosupplementation, are a treatment op-
tion for knee OA that serves to restore the decreasing
rheological properties of synovial fluid. KARTILAGE®
CROSS is a new visco-elastic gel of highly purified
reticulated HA. It contains mannitol to provide an anti-
oxidative action and to avoid HA depolymerization [5].
Reticulation [6, 7] and mannitol [8–10] increase the
residency time of the product in the joint cavity then
allowing a single injection in painful knee OA patients.
The US food and drugs administration (FDA) and
European medicine agency (EMA), have recently pub-
lished guidelines recommending a higher level of integra-
tion of biomarkers in the development and testing of new
drugs to advance decision-making on dosing, time and
treatment effect, trial design, and risk/benefit analysis [11].
Biomarkers can be used not only in the process of drug
development, but also in the future in assessment of
individual patient’s response to treatment as previously
described by Kraus et al. [12]. By evaluating the biomarker
results, clinicians will be able to conclude whether the
treatment has the expected effect or not.
Several soluble biomarkers have been identified as po-
tential candidates to predict or monitor the efficacy of
intervention in OA [13]. Among them, type II collagen
derivatives have been extensively investigated [14–17].
Coll2-1, a degradation product of type II collagen, has
been found in high concentrations in the synovial fluid
of human patients with OA compared with healthy con-
trols [18]. This product is generated by the sequential
action of collagenase and gelatinase B on type II collagen
molecules causing the release of metabolites into syn-
ovial fluid [19]. When measured in serum of patients
with OA it was found to be in higher concentrations
than age-matched controls [18]. Interestingly, Coll2-1
has been shown to be decrease in serum of patients with
knee OA after a series of 3 injections of hylan GF-20,
suggesting that this biomarker could be helpful for the
monitoring of IAHA effect [20]. Coll2-1 is a biomarker
of OA that entered the qualification process [21]. Previ-
ous studies suggested its potential use for the diagnosis,
the prognosis, the burden of disease, and the monitoring
of a treatment efficacy. Indeed, it was shown that serum
Coll2-1 level increased in OA population by comparison
to asymptomatic control group [18]. Moreover, serum
Coll2-1 concentration decreased from 6 months after
total joint replacement [22]. In urine, the increase of
Coll2-1 over 12 months is predictive of radiological OA
progression [23]. In preclinical studies, Coll2-1 was
qualified as biomarker of burden of disease as the in-
crease of the concentration of the biomarker in serum
correlated with the histological severity and the global
macroscopic score [24, 25]. Finally, in human clinical
trials, Coll2-1 was used to monitor the efficacy of intra-
articular viscosupplementation [20] and joint health food
supplement [26].
In general, soluble biomarkers are measured in serum
and/or in urine. Even if biomarkers level in synovial fluid
better reflects what happens in a single joint, synovial
fluid collection remains difficult, biomarkers level
standardization requires measurement of urea in serum
[27], and analytical performance of the assay lower in
this fluid due to its rheological properties.
The aim of this study was to evaluate the effects on
Coll2-1, a biomarker of cartilage degradation, of an
intra-articular injection of hyaluronic acid KARTILAGE®
CROSS versus placebo in patients suffering from knee
pain. Coll2-1 was measured by an immunoassay that
shows very good analytical performances in serum. In
addition, clinical efficacy and tolerance for the product
were investigated as well as the correlation between
Coll2-1 and clinical parameters.
Methods
Study design and study population
This study was designed as a 6-month pilot prospective
comparative randomized double blind trial testing a new
reticulated HA supplemented with mannitol (IAHA)
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versus saline solution injection in ambulatory knee OA
patients.
The study protocol was approved by ethic committee
(CPP Ile de France IV) and French national authorities
(Agence Nationale de Sécurité du Médicament) (RCB
#2012-A01521-42). It was conducted in strict accordance
with the declaration of Helsinki and GCP principles. Each
patient received and signed an informed consent.
The study was conducted between May 15, 2013 and
October 28, 2014.
Eligibility of patients
Eligible patients were men or women, aged between 45
and 80 years suffering of unilateral symptomatic femoro-
tibial knee OA responding to clinical and radiologic
ACR (American College of Rheumatology) criteria [28].
OA must have been symptomatic for more than
6 months with a mean global knee pain determined on
visual analog scale (VAS) for the last 24 h over 40 mm
(without any NSAIDs or analgesics for at least 48 h).
Kellgren and Lawrence (K&L) radiological stage must
have been II or III. The recruited patients must have
required a treatment with hyaluronic acid after failure or
intolerance to first line analgesics or NSAIDs. Patients
signed their informed consent after receiving compre-
hensive information.
Exclusion criteria
The exclusion criteria were selected to avoid the pres-
ence of a contraindication to treatment or diseases
affecting biomarkers clearance and to exclude the
interference of concomitant painful condition or therap-
ies that may modulate cartilage metabolism. Patients
meeting to at least one of the criteria detailed in Table 1
were not included in the study.
Prohibited/authorized treatments
To treat painful condition the following treatments were
authorized throughout the study if necessary.
 Acetaminophen (3 g/day) or NSAID at the lowest
dose and for the shortest possible period of time.
 Topical NSAIDs
 Non-pharmacologic therapy such as orthosis and
physical therapy
These treatments are commonly use in OA clinical
trials as rescue treatments for ethical reasons. Number of
days of intake of acetaminophen and oral NSAIDs during
the month preceding each visit was recorded. However,
NSAIDs in suppository or injected through intra-
muscular injection, oral corticosteroids, intra-articular
injection of corticosteroids, intra-articular injection of
hyaluronic acid were forbidden to avoid interaction with
outcome results. Slow acting treatments against OA (i.e.
chondroitin sulfate, diacerein, avocado soybean unsaponi-
fiable or glucosamine) were allowed throughout the study
duration if their dosage was not modified.
Intervention and randomization
Fifteen combinations of an evaluator physician [general
practitioner (GP) or rheumatologist] and an independent
injector physician (rheumatologist) of 15 different institu-
tions were involved in the study. Evaluator physician was
in charge of patient selection and blinded patient follow
up. The randomization list was established using software.
Patients were followed from 10 days before injection
(D-10) to 180 days after injection (D180). Inclusion and
exclusion criteria were checked at D-10 (inclusion visit)
and history of knee OA was recorded. On D0 patients
were randomized and were injected (injection visit) into
Table 1 Exclusion criteria
Related to the OA pathology
○ Radiographical Kellgren and Lawrence grade I or IV
○ Osteoarthritis secondary to a microcrystalline arthropathy:
chondrocalcinosis previously known or defined by a calcium
border on at least one tibiofemoral spacing, gout ……
○ Isolated femoropatellar OA
○ Presence of another joint (other than the evaluated knee)
affected by OA (confirmed in radiographs and symptomatic)
○ Chondromatosis or villonodular synovitis of the knee
○ Paget disease
○ Recent trauma (<1 month) of the evaluated knee
○ Pathologies interfering with the evaluation of OA (radiculalgia
in the lower limbs, arteritis…..)
○ Acute inflammatory osteoarthritis (Kofus≥ 7)
Related to previous and concomitant treatments
○ Corticosteroids injection in the evaluated knee in the last
month before injection
○ Hyaluronan injection in the evaluated knee in the last
6 months before injection
○ Acetaminophen and NSAIDs 48 h before inclusion visit
○ Change in the dosage of symptomatic slow-acting drugs i.e.
chondroitin, glucosamine, diacerein or avocado-soybean
unsaponifiables in the last 3 months before first injection
○ Arthroscopy and surgery in the target knee in the last
3 months before first injection
○ Oral corticotherapy
Related to associated pathologies
○ Severe diseases (liver or renal failure, uncontrolled
cardiovascular diseases….)
○ Other inflammatory rheumatic diseases (e.g. rheumatoid
arthritis)
○ Dermatological infection at the site of injection
○ Anticoagulant treatment
○ High risk of hemorrhage
Related to the patients
○ Allergy to hyaluronan and constituents (i.e. mannitol)
○ Allergy to acetaminophen
○ Pregnant or breastfeeding women
○ Premenopausal women without contraception
○ Unable to write
○ Participation to a therapeutic clinical trial in the last 3 months
○ Under guardianship or judicial protection
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the evaluated knee under aseptic conditions with either
Kartilage® Cross, a new reticulated HA supplemented
with mannitol (Vivacy, France, 2.2 mL, 16 mg/ml) or sa-
line solution (2.2–2.5 mL, NaCl 9 g/L). The blinded sy-
ringes were prepared and provided by the sponsor.
Injected products were visually similar.
Serum preparation and Coll2- 1 immunoassay
Blood collection was done on non-SST dry tubes with-
out heparin. Blood samples were allowed to clot at room
temperature for +/− 30 min; the tubes were centrifuged
5–10 min at 2000 rpm at 4 °C. The serum was harvested
and stored at −20 °C until assay.
Coll2-1 has been determined in patients’ sera using
ELISA kits according to manufacturers’ instructions
(Artialis SA, Liège, Belgium). This assay is a competitive
immunoassay utilizing a synthetic peptide pre-coated onto
the ELISA plate for the quantification of the correspond-
ing antigen in serum samples. A binding competition be-
tween the immobilized peptide and the peptide contained
in the standards or samples takes place upon addition of
the antibody Ab-Coll2-1. After removal of the unbound
peptide, a peroxidase-conjugated goat anti-rabbit antibody
is added into each well to detect and quantify the level of
competitive binding. After washing of the unbound detec-
tion antibody, the antibody-antigen complex is detected
by a chromogenic reaction with 3,3’,5,5’-tetramethylbenzi-
dine (TMB). The reaction is stopped by adding acid to
give a colorimetric endpoint that is subsequently deter-
mined spectrophotometrically. The limits of quantification
for the assay ranged from 31.25 nM to 2000 nM.
Outcome measures
Primary outcome
The main objective of this study was to evaluate the ef-
fect of IAHA on cartilage metabolism. In this purpose,
we selected the most cartilage specific sequence Coll2-1.
This type II collagen sequence is released during cartil-
age degradation by metalloproteases and directly mea-
sured in the serum using an immunoassay. The primary
outcome was the percentage of patients with a reduc-
tion of at least 10 nmol/l of serum Coll2-1 between
visit (D-10) and D90 (3 months after injection). The
cut-off value of 10 nmol/l was based on the measure-
ment error of the serum Coll2-1 immunoassay. The
smallest detectable difference (SDD) of the serum
Coll2-1 immunoassay was evaluated by the method of
Bland and Altman [29] from 22 sera measured two
times at two different days.
Secondary outcomes
The secondary outcomes (Table 2) included the change
in Coll2-1 levels between inclusion (D-10), D30, and
D180 in order to document changes in Coll2-1 levels
throughout the study. Additionally, changes in pain and
function as well as the use of rescue medication were
considered.
Tolerance
Tolerance was assessed through the monitoring of ad-
verse events (AEs). Each one was detailed. The patients’
global tolerance to the study product was also recorded
(scale 0–5, ranging from 0: excellent to 5: very bad).
Statistical analysis
Populations
Several populations were defined.
The population of included patients corresponded to
the patients who were selected and included in the study
on D-10.
The intent to treat (ITT) population corresponded to
the included and randomized patients.
The tolerance population comprised all randomized
patients, having received the intra-articular injection
with the study product.
The full analysis set (FAS) population represented all
randomized patients, having received the intra-articular
injection of the study product, being evaluated for the
primary outcome on D-10 and at least once after the
injection of the study product. Missing values were
handled with the LOCF (last observed carried forward)
technique. This means that D-10 data should be
available and that if D90 data was missing, the result of
the closest measurement was taken into account.
Per protocol (PP) population corresponded to all
patients of the FAS population who did not present any
major defined deviation. The protocol defined as major
the following deviations:
Table 2 Secondary outcomes
Parameter Method of analysis
Coll2-1 Decrease between inclusion (D-10)
and D30 or D180
Lequesne index (LI) Decrease between inclusion visit
(D-10) and further visits
Global assessment of pain Visual analog scale (VAS, 0–100 mm)
between inclusion visit (D-10) and
further visits




Number of patients that required at
least once rescue medication during
the study
Patient’s global assessment of
the disease activity
11 points Likert scale ranging of 0
(low active disease) to 10 (maximum
activity)
Abbreviations: OMERACT Outcome Measures in Rheumatology, OARSI
Osteoarthritis Research Society International, D-10 10 days before injection,
D30, D90, D180 respectively 30, 90, and 180 days following injection
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– Those related to inclusion or exclusion criteria
– Missing of the primary outcome on D90
– Intake of a treatment that was forbidden and that
could have an important impact on the primary
outcome
– Any deviation that could have a major impact on
the primary outcome.
Sample size
HA injections in a previous study including 45 patients
produced a decrease in Coll2-1 superior to 10 nmol/l in
48% of the patient [20]. The hypothesis was made that
Kartilage® Cross treatment in this study will produce a
decrease of 10 nmol/l of Coll2-1 between inclusion and
D90 in the serum in 45% of the patients. Hence 35
patients per group would produce a difference of 33%
with placebo group (12% expected in the placebo group)
considering a risk of 5% and a power of 80% (Fleiss
method with continuity correction). Taking into account
patients who would be out of the study, the number of
patients per group was defined as 40.
Analysis of the primary outcome
The analysis of the efficacy primary outcome (% of
patients with a reduction of at least 10 nmol/l of serum
Coll2-1 between D-10 and D90) was performed on the
FAS population using the LOCF. A Chi-square test or a
Fisher Exact was used. Sensitivity analysis were done on
FAS population without handling of missing data
(analysis on observed cases) and on PP population.
Analysis of the secondary outcomes
The change in both clinical and biological parameters
was analyzed if the distribution of the population was
normal, using an ANCOVA with an adjustment on the
basal value. In case of non-normal distribution, a non-
parametric test was used. Analyses were conducted on
the FAS population. LOCF approach was considered to
deal with missing data. Data were analyzed at each time
point versus baseline (between D-10/D30, D-10/D90,
and D-10/D180) and were completed by an ANOVA for
repeated measures based on the time D-10/D30/D90/
D180 and the treatment if applicable.
Response to the test product according to OMERACT/
OARSI criteria were analyzed using a Chi-square test at
D30, D90 and D180 on the FAS population dealing with
missing data (VAS and LI) using the LOCF approach. The
consumption of acetaminophen and NSAIDs were com-
pared between groups with a Chi-square test or Fisher
Exact test on the FAS population without considering
missing data on D30, D90 and D180.
Assessment of safety
The percentage of patient with at least one AE, one ser-
ious AE, one AE attributable to the intervention, one AE
attributable to the product, and one event leading to
study stopping were recorded. The percentage of the
most frequent local or systemic events were calculated
and compared using a Chi-square test or Fisher Exact
test depending on their occurrence. They were presented
with regards to their link to the product, their evolution
and the therapeutic decision. The serious intercurrent
events were described and compared.
The global tolerance appreciated by the patient was
analyzed using a non-parametric test on rank values.
Results
Study populations
Eighty four (84) patients were selected. Three of them
did not attend the injection visit and were not random-
ized in the study. Eighty one (81) patients were random-
ized in the study: 40 in the treatment group and 41 in
the saline solution group. Four patients finished prema-
turely the study: one (2.5%) from the treatment group
due to AE, 3 (7.3%) from the saline solution group (one
for AE, one for AE and inefficacy, one for loss of follow
up at D180). Five patients in the treatment group (17%)
and 10 (30%) in the saline solution group presented a
major deviation to protocol. Major deviations were re-
lated to the non-respect of delays between visits. The
ITT and FAS populations contained 81 patients (40 in
the treatment group and 41 in the saline solution group)
and the PP population contained 66 patients (35 in the
treatment group and 31 in the saline solution group).
Patient characteristics
Both groups of the study were not statistically different
for their demographic and morphological criteria
(Table 3). Patients were mainly women (69.1%) with a
mean age of 65.0 ± 9.8 years and a mean body mass
index (BMI) of 29.9 ± 7.3 kg/m2. Patients were suffering
from OA for 6.7 ± 6.8 years. 55.6% (n = 45) had a K&L of
II and 44.4% (n = 36) of III and 54.3% (n = 44) had pain
during night. 49.4% of patients had not taken any treat-
ment for OA for the past 3 months. 32.1, 13.6 and 8.6%
had taken analgesics, NSAIDs and/or slow acting anti
OA drugs respectively. No significant difference was
reported between groups for either parameter.
Primary efficacy outcome
The percentage of patient with a reduction of at least
10 nmol/l of serum Coll2-1 between D-10 and D90 was
52.5% in the treatment group and 31.7% in the placebo
group in the FAS population when dealing with the
missing values. This difference was not statistically
significant (P = 0.0580).
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The sensitivity analysis of the primary outcome re-
vealed a significant difference between the two groups in
the FAS population without handling the missing values.
56.8% of the patients in the treatment group had a re-
duction of at least 10 nmol/l of serum Coll2-1 between
D-10 and D90 whereas 28.6% in the placebo group did
(P = 0.0158) (Table 4). The same statistically significant
difference was observed in the PP population without
considering the missing data (Table 5).
The percentage changes in each patient's biomarker
levels from baseline to D90 (primary outcome) was
calculated and displayed on Fig. 1.
The number of patients showing a decrease in Coll2-1
was higher in the Kartilage Cross (22/37) group than, in
the placebo group (10/34). Inversely, more patients
showed an increase of Coll2-1 in the placebo (20/34)
than in the Kartilage cross group (9/37).
Secondary efficacy outcomes
Biological efficacy
The biological efficacy of the treatment was evaluated
using the variation in Coll2-1 between inclusion (D-
10) and D30 or D180 as secondary outcome.
No statistically significant difference was observed
regarding the change in Coll2-1 from inclusion to
D30. However, change in Coll2-1 between D-10 and
D180 showed statistically significant difference be-
tween groups (−34.5 ± 49.7 nmol/l for IAHA vs 43.5
± 49.0 nmol/l for placebo, P = 0.0473, Table 6).



















BMI (kg/m2) 29.0 ± 7.4 30.8 ± 7.2 29.9 ± 7.3 0.2465 Student
Disease duration (year) 7.6 ± 8.0 5.9 ± 5.3 6.7 ± 6.8 0.2639 Student
Evaluated knee
- Right 45.0% 48.8% 46.9%
- Left 55.0% 51.2% 53.1% 0.7332 Chi-square test
Radiological score (K&L)
- Score II 52.5% 58.5% 55.6%
- Score III 47.5% 41.5% 44.4% 0.5846 Chi-square test
Night pain 52.5% 56.1% 54.3% 0.7452 Chi-square test
Effusion 20.0% 14.6% 17.3% 0.5231 Chi-square test
OA treatment for the past 3 months
- Acetomiphen 27.5% 41.5% 32.1% 0.2155 Chi-square test
- NSAIDS 15.0% 12.2% 13.6% 0.7126 Chi-square test
- slow acting anti OA drugs 7.5% 9.8% 8.6% 0.7179 Chi-square test
Table 4 Variation of serum Coll2-1 between D-10 and D90 in the FAS population without handling the missing values
IAHA
N = 40 at D-10
N = 37 at D90
Saline solution
N = 41 at D-10
N = 35 at D90
P value Test














Reduction of at least 10 nmol/l 56.8% 28.6% 0.0158* Chi-square test
aShapiro-Wilk normality test < 0.0001, basal value was used as covariate
**p < 0.01, *p < 0.05
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Clinical efficacy (Table 7)
No statistically significant difference was observed
between groups regarding the change in function (LI) or
pain (VAS). There was also no difference regarding the
OMERACT-OARSI responders and the patient global
assessment on disease activity.
Rescue medication No significant difference (FAS
population) was observed between the 2 groups regard-
ing the consumption of acetaminophen (50.0% vs 53.7%
between D0 and D30, 55.0% vs 52.5% between D30 and
D90 and 35.0% vs 47.4% between D90 and D180 for
IAHA and saline solution respectively) and or NSAIDs
(7.5% vs 7.3% between D0 and D30, 7.5% vs 7.5%
between D30 and D90 and 10.0% vs 2.6% between D90
and D180 for IAHA and saline solution respectively).
Tolerance Thirty AEs were reported in 29 patients
among 81 (35.8%) during the study, 14 in the IAHA
group and 15 in the saline solution group. Two AEs
were considered attributable to the product, one joint ef-
fusion in the treatment group and one inflammation at
the injection site in the saline solution group. Three AE
were considered as serious, one in the treatment group
and 2 in the placebo group. None of them was consid-
ered as related to the product or the procedure of
injection.
Discussion
This is the first clinical trial designed in order to study
the effect of IAHA in knee OA patients on serum levels
of Coll2-1, a biomarker OA of cartilage degradation.
Despite the absence of significant effect on the primary
end-point, this study shows that a single intra-articular
injection of a new reticulated HA supplemented with
mannitol may reduce serum levels of Coll2-1. Coll2-1 is
a degradation product of type II collagen released during
cartilage degradation.
This study is confirmatory of the BIOVISCO study
demonstrating that three injections of hylan G20 de-
creased serum Coll2-1 [20]. This also confirms the sensi-
tivity of this biomarker to metabolic change occurring in
a single joint. Another key observation was the absence
of relationship between Coll2-1 variation and the clinical
response, probably due to the absence of effects of the
product on symptoms.
This study is an additional step in the qualification of
Coll2-1. A biomarker is defined as a characteristic that is
objectively measured and evaluated as an indicator of nor-
mal biologic processes, pathogenic processes, or pharma-
cologic responses to a therapeutic intervention. Among
other things, biomarkers in the OA field can be used in
drug development, treatment monitoring and the future
basis of personalized evidence-based action plans. Accord-
ing the BIPED classification, an efficacy of intervention
biomarker has to be indicative or predictive of treatment
efficacy. The concentration of this biomarker has to differ
significantly between patient populations with or without
treatment, or before and after within patient. Based on
our results, Coll2-1 could be considered as a valuable tool
for monitoring IAHA effect at an individual level. Of
course, large cohort and meta-analysis performed on some






Serum Coll2-1 at D-10 859.2 ± 396.6 763.7 ± 389.8 0.3288 ANOVA
Serum Coll2-1 at D90 745.9 ± 353.1 767.4 ± 204.0 0.7674 ANOVA




Reduction of at least 10 nmol/l 57.1% 29.0% 0.0217* Chi-square test
aShapiro-Wilk normality test < 0.0001, basal value was used as covariate
**p < 0.01, *p < 0.05
Fig. 1 Individual change of Coll2-1 level in serum of patient receiving placebo (a) or treated with Kartilage Cross (b)
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clinical study should be conducted to complete the qualifi-
cation process of this marker.
An intriguing result is the absence of effects of IAHA
on the clinical parameters, while some previous studies
have reported a beneficial effect [30, 31]. The absence of
clinical effect may be explained by the design of the
study built to study the effects of HA on Coll2-1. For
example, the sample size was estimated to detect an
effect on Coll2-1, but not to detect an effect on algo-
functional status. Another explanation may be the lack
of correlation between the degradative process illus-
trated by the serum levels of biomarkers and the clinical
evolution. Moreover, the population is composed in
majority by women with unilateral knee OA, two factors
of prognosis of a lesser clinical responses. The criteria
chosen in this study for clinical evaluation were the one
classically used and previously defined by Altman et al.
[28]. In addition the placebo effect was clearly described
in OA patients, especially after an invasive intervention
as IA injection [32]. This is then paramount to design
clinical trial that will not only prove the clinical efficacy
of a treatment but also the relevance of biomarkers.
This study has several limitations. One the major limi-
tation is that the effect is significant on the FAS popula-
tion if the missing value were not handled, but not if
this missing value were replaced by the LOCF. A second
concern was the absence of clinical efficacy of the prod-
uct. This limits the possibility to correlate biomarker
Table 6 Variation of serum Coll2-1 between D-10 and D180 in the FAS population without handling the missing values
IAHA
N = 40 at D-10
N = 35 at D180
Saline solution
N = 41 at D-10
N = 36 at D180
P value Test














aShapiro-Wilk normality test < 0.0001, basal value was used as covariate
*p < 0.05
Table 7 Change in clinical secondary outcome on the FAS population (LOCF approach)
D-10 D30 D90 D180 Test
LI Treatment group (N = 40) 12.5 ± 3.8 8.3 ± 4.1 8.2 ± 4.3 6.8 ± 4.9 ANOVA
Placebo group (N = 41) 12.5 ± 3.4 9.0 ± 5.0 8.9 ± 5.5 8.1 ± 5.5
P value 0.9500 0.4983 0.5466 0.3395
Change in pain (VAS) Treatment group (N = 40) 65.7 ± 11.6 35.9 ± 21.5 31.4 ± 24.2 27.9 ± 23.2 ANOVA
Placebo group (N = 41) 66.4 ± 9.8 38.6 ± 21.6 36.2 ± 25.6 30.8 ± 23.9
P value 0.7719 0.5659 0.3939 0.5738
Change in pain intensity adjusted to basal value (VAS) Treatment group (N = 40) – −30.1 ± 3.4 −34.8 ± 3.9 −38.2 ± 3.7 ANOVA
Placebo group (N = 41) – −27.5 ± 3.4 −29.7 ± 3.8 −35.2 ± 3.7
P value – 0.5925 0.3543 0.5576
Change in pain intensity responder 30% (VAS) Treatment group (N = 40) – 60.0% 70.0% 72.5% Chi-square test
Placebo group (N = 41) – 61.0% 65.9% 75.6%
P value – 0.9284 0.6894 0.7495
Change in pain intensity responder 50% (VAS) Treatment group (N = 40) – 50.0% 50.0% 57.5% Chi-square test
Placebo group (N = 41) – 43.9% 43.9% 63.4%
P value – 0.5825 0.5825 0.5862
%OMERACT -OARSI responders/non-responders Treatment group (N = 40) – 70.0% 70.0% 67.5% Chi-square test
Placebo group (N = 41) – 70.7% 65.9% 61.0%
P value – 0.9425 0.1597 0.3750
Patient global assessment on disease activity Treatment group (N = 40) 6.6 ± 1.3 3.6 ± 1.9 3.4 ± 2.5 2.9 ± 2.1 ANOVA
Placebo group (N = 41) 6.4 ± 1.3 4.0 ± 2.1 4.1 ± 2.5 3.5 ± 2.4
P value 0.6411 0.447 0.2052 0.2444
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levels with clinical outcomes and then to qualify the bio-
marker as a marker of efficacy. Moreover it was designed
as a pilot study and even though it allowed obtaining
significant results in a small number of patients. Finally,
our biomarker assessment is limited to Coll2-1, a bio-
marker of type II collagen degradation. The measure-
ment of a biomarker evaluating type II collagen
synthesis would have been helpful to better appreciate
the effect of IAHA on cartilage metabolism. Further in-
vestigations would confirm and detail the effect of this
reticulated HA formulation.
Conclusion
For the first time, this study demonstrated that IAHA
decreased significantly serum Coll2-1, a maker of cartil-
age catabolism, compared to the injection of a saline
solution. This finding suggests that IAHA may have a
beneficial on cartilage degradation and suggests that
Coll2-1 could be used for the assessment of a single
intra-articular treatment in clinical trials.
Abbreviations
ACR: American college of rheumatology; AE: Adverse event; D: Day;
EMA: European medicine agency; FAS: Full Analysis Set; FDA: Fodd and drug
administration; GP: General practitioner; HA: Hyaluronic acid; IA: Intra-articular;
ITT: Intent To Treat; K&L: Kellgren and Lawrence; LI: Lequesne index;
LOCF: Last observation carried forward; NSAID: Non-steroidal anti-
inflammatory drug; OA: Osteoarthritis; OARSI: Osteoarthritis research society
international; OMERACT: Outcome Measures in Rheumatoid Arthritis Clinical
Trials; PP: Per propocol; VAS: Visual analog scale
Acknowledgments
This study was granted by VIVACY. YH is the coordinator of the WP1 of the
D-BOARD Consortium funded by European Commission Framework 7 program
(EU FP7; HEALTH.2012.2.4.5-2, project number 305815, Novel Diagnostics and
Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases).
Funding
This study was funded by Laboratories VIVACY, France.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
YH, FR, XC, MM, PR, FR conceived and designed the study; YH, FR, XC, MM,
PR, FR acquired the data, or analysed and interpreted the data; YH, FR, XC,
MM, PR and FR drafted and revised the manuscript; YH, FR, XC, MM, PR and
FR provided final approval of the version to be published.
Competing interests
YH is the founder of Artialis SA a spin-off company of the University of Liège.
He also received fees from Flexion, Ibsa, Expansciences, KiOmed Pharma SA
(formerly Synolyne Pharma SA), Tilman SA, Bepharbel, Labhra.
FB received fees from Ibsa, BioIberica, Expanscience, Servier, Flexion, Pfizer,
Abbvie, Merck, Janssen, Sanofi, Regeneron and Rottapharm.
XC received fees from Genevrier, Sanofi, Servier, Moebius, Flexion Therapy,
Ibsa, Nordic Pharma and Expanscience.
MM received in directly fees for advisory board from Artialis.
PR received fees from Artialis, Ibsa, Bioiberica, Fidia, Expanscience, Genevrier,
Sanofi, Servier, Flexion, Pfizer, Rottapharm, Daichi-Sankyo.
FR received fees from Expanscience, Servier, Menarini, Rottapharm, Genévrier,
Pierre Fabre, MSD, GSK, and Sanofi.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was approved by ethic committee (CPP Ile de France IV)
and French national authorities (Agence Nationale de Sécurité du
Médicament) (RCB #2012-A01521-42). It was conducted in strict accordance
with the declaration of Helsinki and GCP principles. Each patient received
and signed an informed consent.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Bone and Cartilage Research Unit, Arthropole Liège, CHU Sart-Tilman, Liège,
Belgium. 2Rheumatology Department, Sorbonnes Universités UMPC Univ
Paris 06, Inserm UMRS 938, DHU i2B, Saint Antoine Hospital, Assistance
Publique—Hôpitaux de Paris (AP-HP), Paris, France. 3Service de
Rhumatologie, Hôpital Henri Mondor, Créteil, France. 4Service de
Rhumatologie - Centre Viggo Petersen, Hôpital Lariboisière, Paris, France.
5University Paris Descartes, PRES Sorbonne Paris Cité, Service de rééducation
et réadaptation de l’appareil locomoteur et des pathologies du rachis,
Hôpital Cochin, AP - HP, INSERM UMR-S-1124, UFR Biomédicale des Saints
Pères, Paris, France.
Received: 9 November 2016 Accepted: 17 May 2017
References
1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World
Health Organ. 2003;81(9):646–56.
2. Felson DT. Identifying different osteoarthritis phenotypes through
epidemiology. Osteoarthritis Cartilage. 2010;18(5):601–4.
3. van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms.
Osteoarthritis Cartilage. 2011;19(4):338–41.
4. Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010;
26(3):355–69.
5. Conrozier T, Mathieu P, Rinaudo M. Mannitol Preserves the Viscoelastic
Properties of Hyaluronic Acid in an In Vitro Model of Oxidative Stress.
Rheumatol Ther. 2014;1(1):45–54.
6. Abate M, Pelotti P, De Amicis D, Di Iorio A, Galletti S, Salini V.
Viscosupplementation with hyaluronic acid in hip osteoarthritis (a review).
Ups J Med Sci. 2008;113(3):261–77.
7. Tikiz C, Unlu Z, Sener A, Efe M, Tuzun C. Comparison of the efficacy of lower
and higher molecular weight viscosupplementation in the treatment of hip
osteoarthritis. Clin Rheumatol. 2005;24(3):244–50.
8. Belda JI, Artola A, Garcia-Manzanares MD, Ferrer C, Haroun HE, Hassanein A,
Baeyens V, Munoz G, Alio JL. Hyaluronic acid combined with mannitol to
improve protection against free-radical endothelial damage: experimental
model. J Cataract Refract Surg. 2005;31(6):1213–8.
9. Frati E, Khatib AM, Front P, Panasyuk A, Aprile F, Mitrovic DR. Degradation of
hyaluronic acid by photosensitized riboflavin in vitro. Modulation of the
effect by transition metals, radical quenchers, and metal chelators. Free
Radic Biol Med. 1997;22(7):1139–44.
10. Mendoza G, Alvarez AI, Pulido MM, Molina AJ, Merino G, Real R, Fernandes
P, Prieto JG. Inhibitory effects of different antioxidants on hyaluronan
depolymerization. Carbohydr Res. 2007;342(1):96–102.
11. Kraus VB, Blanco FJ, Englund M, Henrotin Y, Lohmander LS, Losina E,
Onnerfjord P, Persiani S. OARSI Clinical Trials Recommendations: Soluble
biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis
Cartilage. 2015;23(5):686–97.
12. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J,
Garnero P, Hardin J, Henrotin Y, et al. Application of biomarkers in the
development of drugs intended for the treatment of osteoarthritis.
Osteoarthritis Cartilage. 2011;19(5):515–42.
13. Rousseau J, Garnero P. Biological markers in osteoarthritis. Bone. 2012;51(2):
265–77.
14. Birmingham JD, Vilim V, Kraus VB. Collagen biomarkers for arthritis
applications. Biomark Insights. 2007;1:61–76.
Henrotin et al. BMC Musculoskeletal Disorders  (2017) 18:222 Page 9 of 10
15. Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in
osteoarthritis: what do they indicate? Curr Opin Rheumatol. 2007;19(5):444–50.
16. Landsmeer ML, Runhaar J, Henrotin YE, van Middelkoop M, Oei EH,
Vroegindeweij D, Reijman M, van Osch GJ, Koes BW, Bindels PJ, et al.
Association of urinary biomarker COLL2-1NO with incident clinical and
radiographic knee OA in overweight and obese women. Osteoarthritis
Cartilage. 2015;23(8):1398–404.
17. Mobasheri A, Bay-Jensen AC, van Spil WE, Larkin J, Levesque MC.
Osteoarthritis Year in Review 2016: biomarkers (biochemical markers).
Osteoarthritis Cartilage. 2017;25(2):199–208.
18. Deberg M, Labasse A, Christgau S, Cloos P, Bang Henriksen D, Chapelle JP,
Zegels B, Reginster JY, Henrotin Y. New serum biochemical markers (Coll 2-1
and Coll 2-1 NO2) for studying oxidative-related type II collagen network
degradation in patients with osteoarthritis and rheumatoid arthritis.
Osteoarthritis Cartilage. 2005;13(3):258–65.
19. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C,
Mitchell P, Hambor J, Diekmann O, Tschesche H, et al. Enhanced cleavage
of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin
Invest. 1997;99(7):1534–45.
20. Henrotin Y, Chevalier X, Deberg M, Balblanc JC, Richette P, Mulleman D,
Maillet B, Rannou F, Piroth C, Mathieu P, et al. Early decrease of serum
biomarkers of type II collagen degradation (Coll2-1) and joint inflammation
(Coll2-1 NO(2)) by hyaluronic acid intra-articular injections in patients with
knee osteoarthritis: a research study part of the Biovisco study. J Orthop
Res. 2013;31(6):901–7.
21. Mobasheri A, Henrotin Y. Identification, validation and qualification of
biomarkers for osteoarthritis in humans and companion animals: mission for
the next decade. Vet J. 2010;185(2):95–7.
22. Deberg M, Dubuc JE, Labasse A, Sanchez C, Quettier E, Bosseloir A, Crielaard
JM, Henrotin Y: One year follow-up of Coll2-1, Coll2-1NO2 and
myeloperoxydase serum levels in oa patients after hip or knee replacement.
Ann Rheum Dis. 2008;67:168–74.
23. Deberg MA, Labasse AH, Collette J, Seidel L, Reginster JY, Henrotin YE. One-
year increase of Coll 2-1, a new marker of type II collagen degradation, in
urine is highly predictive of radiological OA progression. Osteoarthritis
Cartilage. 2005;13(12):1059–65.
24. Huebner JL, Williams JM, Deberg M, Henrotin Y, Kraus VB. Collagen fibril
disruption occurs early in primary guinea pig knee osteoarthritis.
Osteoarthritis Cartilage. 2010;18(3):397–405.
25. Henrotin Y, Martel-Pelletier J, Msika P, Guillou GB, Deberg M. Usefulness of
specific OA biomarkers, Coll2-1 and Coll2-1NO2, in the anterior cruciate
ligament OA canine model. Osteoarthritis Cartilage. 2012;20(7):787–90.
26. Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E,
Bonnet V, Castermans C. Decrease of a specific biomarker of collagen degradation
in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an
exploratory clinical trial. BMC Complement Altern Med. 2014;14(1):159.
27. Kraus VB, Huebner JL, Fink C, King JB, Brown S, Vail TP, Guilak F. Urea as a
passive transport marker for arthritis biomarker studies. Arthritis Rheum.
2002;46(2):420–7.
28. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke
TD, Greenwald R, Hochberg M, et al. Development of criteria for the
classification and reporting of osteoarthritis. Classification of osteoarthritis of
the knee. Diagnostic and Therapeutic Criteria Committee of the American
Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–49.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet. 1986;1(8476):307–10.
30. Henrotin Y, Raman R, Richette P, Bard H, Jerosch J, Conrozier T, Chevalier X,
Migliore A. Consensus statement on viscosupplementation with hyaluronic acid
for the management of osteoarthritis. Semin Arthritis Rheum. 2015;45(2):140–9.
31. Cooper C, Rannou F, Richette P, Bruyere O, Al-Daghri N, Altman RD, Luisa
Brandi M, Collaud Basset S, Herrero-Beaumont G, Migliore A, et al. Use of
Intra-Articular Hyaluronic Acid in the Management of Knee Osteoarthritis in
Clinical Practice. Arthritis Care Res 2017. doi:10.1002/acr.23204.
32. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect
and its determinants in osteoarthritis: meta-analysis of randomised
controlled trials. Ann Rheum Dis. 2008;67(12):1716–23.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Henrotin et al. BMC Musculoskeletal Disorders  (2017) 18:222 Page 10 of 10
